Drug or treatment

Famitinib clinical trials

• 7Clinical trials
• 1Country

Newest trials

All recruiting trials (7)

• Perioperative therapy with Retlirafusp alfa, Famitinib, and HAIC-GEMOX for locally advanced intrahepatic cholangiocarcinoma

  This trial tests whether a perioperative treatment combo (Retlirafusp alfa, famitinib, and HAIC-GEMOX) can help shrink or control locally advanced intrahepatic cholangiocarcinoma before surgery and support additional therapy afterward in adults.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07847710

• Neoadjuvant therapy with adebrelimab, famitinib, and chemotherapy for resectable ESCC

  This study tests a combination of adebrelimab, famitinib, and chemotherapy before surgery in people with resectable locally advanced esophageal squamous cell carcinoma to see if it can lead to a complete tumor disappearance at the time of surgery.

  Recruiting Phase 2 First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shannxi · NCT07796113

• Camrelizumab with Famitinib for rare head and neck cancers

  This trial tests whether combining camrelizumab with famitinib can help adults with unresectable or metastatic soft tissue sarcoma, malignant melanoma, adenoid cystic carcinoma, or certain salivary gland cancers who have not tried a PD-1 inhibitor before.

  Recruiting Phase 1/2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07662681

• Adebrelimab with famitinib and irinotecan for advanced stomach cancer after first-line treatment stops working

  This trial will try whether adding the immune drug adebrelimab and the targeted drug famitinib to irinotecan helps people with advanced stomach or gastroesophageal junction cancer whose first-line treatment has stopped working.

  Recruiting Phase 2 Shandong Tumor Hospital · Jinan, Shandong · NCT07309185

• Neoadjuvant treatment for gBRCA-mutated HER2-negative breast cancer

  This study is testing a new treatment combination for women with a specific type of breast cancer linked to BRCA mutations to see if it can work without traditional chemotherapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06516289

• Combining Camrelizumab and Chemotherapy for Triple-Negative Breast Cancer Treatment

  This study is testing if adding a new drug called camrelizumab, with or without famitinib, to standard chemotherapy can improve treatment for people with triple-negative breast cancer before surgery.

  Recruiting at 2 sites Phase 3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT05999149

• Combining Famitinib and Camrelizumab for Treating Advanced Triple-Negative Breast Cancer

  This study is testing if combining Famitinib with Camrelizumab can help people with advanced triple-negative breast cancer do better than just using Camrelizumab with another treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05760378

Quick answers

How many clinical trials of Famitinib are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 3: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →